Background Psychological distress among people with psoriasis may lead to elevated risks of suicide and nonfatal self-harm. Objectives To investigate psychiatric comorbidity, psychotropic medication prescribing and risk of suicidality in people with psoriasis. Methods A cohort of patients with psoriasis (1998-2014) was delineated using the Clinical Practice Research Datalink, with linkage to Hospital Episode Statistics and Office for National Statistics mortality records. Each patient with psoriasis was matched with up to 20 patients without psoriasis on age, sex and general practice. A stratified Cox regression model was used to estimate the hazard ratios (HRs) for suicide or nonfatal self-harm risks adjusted for socioeconomic status. Results At baseline, among 56 961 and 876 919 patients with and without psoriasis, higher prevalence for histories of alcohol misuse, bipolar disorder, depression, anxiety disorders, self-harm and psychotropic drug prescription were observed. The deprivation-adjusted HR indicated lower suicide risk in people with psoriasis [HR 0Á59, 95% confidence interval (CI) 0Á41-0Á85]. The risk of suicide varied according to age: it was lower in people with psoriasis diagnosed at ≥ 40 years (HR 0Á38, 95% CI 0Á21-0Á66), whereas there was no difference in risk of suicide in people with psoriasis diagnosed before age 40 years (HR 0Á92, 95% CI 0Á58-1Á46). Conversely, there was a small increased risk for self-harm (HR 1Á15, 95% CI 1Á04-1Á27) associated with psoriasis. Conclusions The prevalence of mental illness was raised in people with psoriasis, and this may lead to a greater risk of self-harm. Nevertheless, having psoriasis does not appear to be associated with an increased risk of suicide. Healthcare professionals caring for patients with psoriasis should continue to monitor and tackle effectively the psychological needs of these individuals.
same age group, whereas if the diagnosis occurred prior to age 40 years there was no difference in risk between the two groups.
• Conversely, there was a 15% increase in self-harm risk in the psoriasis group vs. the general population.
Psoriasis is a currently incurable, chronic skin disorder. It is among the most common immune-mediated diseases, 1 affecting almost 3% of people in the U.K. 2 The condition is commonly associated with psychiatric comorbidities. [3] [4] [5] [6] [7] Suggested explanations for associated mental illness include the considerable impact that psoriasis has on people's quality of life, 8, 9 mainly related to the appearance of the skin and consequent psychological challenges. 10 It is thought that the psychological burden in people with psoriasis may lead to elevated risk of self-harm and suicide. Several earlier studies have examined possible associations between psoriasis and suicidal ideation, 3, 5, 11 but few population-based studies have been published. 4, 6, [12] [13] [14] Previous studies have investigated composite outcomes (such as suicidal ideation, suicide attempt or suicide combined), 4, 6 have identified people with psoriasis from hospital records 12 or insurance and administrative databases, 6, 14 or have used a hospital register linked to dispensing data. 13 Two recent systematic reviews and meta-analyses examined risk of suicide in people with psoriasis 15, 16 and reached different conclusions. Singh et al. 15 identified 18 studies (including cross-sectional, case-control and cohort studies) that reported on suicidal ideation, attempted suicide or death by suicide. They concluded that people with psoriasis have a raised prevalence of suicidal ideation and elevated risks of both fatal and nonfatal suicidal acts. Conversely, Chi et al. 16 investigated the same outcomes but included only four population-based cohort studies, as these studies are more appropriate to assess the causal relationship between psoriasis and the outcome. 16 They concluded that there was insufficient evidence of an association between psoriasis and suicidality risk, and they also highlighted the need for further research on this important topic. 16 Given the lack of clarity regarding this clinically important issue, we conducted a large population-based cohort study utilizing linked primary care, hospitalization and national mortality records to investigate the prevalence of psychiatric comorbidities, psychotropic medication prescribing and the associations between psoriasis and suicide and self-harm risks.
Patients and methods

Data source and study design
A population-based cohort study was carried out using data from the Clinical Practice Research Datalink (CPRD) linked to the Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality records. The study is reported in line with the recommendations of the RECORD statement. 17 Almost the entire population of the U.K. is registered with a general practice, which plays a key role in the National Health Service (NHS). The CPRD, one of the world's largest longitudinal primary care databases, captures the medical histories (diagnoses, test results, prescriptions and referrals to hospital) of patients registered with a general practice. Published studies have shown that the CPRD yields high-quality data for conducting observational research studies. 18, 19 The current study included data from 398 general practices in England that had consented to linkage to national HES and ONS mortality records. Approximately 60% of all practices based in England are included in the CPRD's routine linkage scheme, with linkage undertaken using patients' unique NHS identification numbers, and information available on sex, date of birth and residential postcode. The study cohort consisted of patients with a first diagnosis of psoriasis recorded using Read codes in their primary care records between 1 January 1998 and 31 March 2014 who were 16 years or older at the index date, who had been registered with the practice for at least 1 year prior to the index date, and who were eligible for linkage to the HES and ONS mortality records. A comparison cohort of patients without psoriasis was identified by matching each patient with psoriasis with up to 20 patients without the disease on age, sex and general practice on the index date. 20 To avoid potential selection, information and detection biases, patients in the comparison cohort were selected from the same population at risk and were identified from the same general practice and during the same time window as the patients with psoriasis they were matched to. This delineated the initial cohort used to investigate the association between psoriasis and suicide risk ( Fig. S1 ; see Supporting Information). Subsequently, from this initial cohort, people with a history of self-harm (at the index date) in either the CPRD or HES were excluded from the analysis. This nested cohort was used to investigate the association between psoriasis and the risk of self-harm. In the analysis of both outcomes, all patients included in the study were followed up from the index date until the end of the study (31 March 2014) or either the last date of data collection, or when the patient was transferred out of the practice, died or experienced one of the outcomes of interest (first nonfatal self-harm event or death by suicide), whichever came first.
Area-level socioeconomic status
Information on small-area-level socioeconomic status was available through linkage of patients' residential postcodes to the Index of Multiple Deprivation (IMD) 2010. 21 The IMD is an ecological measure that is derived via a weighted combination of the following seven domains of deprivation: income, employment, health and disability, education skills and training, barriers to housing and services, living environment and crime. The IMD scores were aggregated into quintiles, where 1 corresponded to the least deprived areas and 5 to the most deprived localities.
Classification of suicide and nonfatal self-harm
People who died by suicide were ascertained using the underlying cause of death as recorded on the death certificate. These were extracted from the linked ONS mortality records using International Classification of Diseases 9th revision (ICD-9) codes E950-E959 and E980-E989 (excluding E988Á8) and International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) codes X60-X84, Y10-Y34 (excluding Y33Á9), Y87Á0 and Y87Á2. The definition of suicide applied was in line with the guidance issued by the ONS, which combines cases where the underlying cause of death was either suicide or an unnatural death of undetermined intent. 22, 23 Unnatural causes of death are returned in England and Wales by a coroner; psychiatrists may provide evidence and expert professional judgement at coronial hearings, but the cause of death is ultimately determined by the coroner. Firstrecorded nonfatal self-harm episodes were identified according to the first entry in either the primary care or hospital records. Read codes were used to identify events from the primary care records, 24 and ICD-9 (E950-E959) and ICD-10 (X60-X84) codes to identify events from HES. All of the code lists used in the study are available from www.clinicalcodes.org. 25 
Statistical methods
Prevalence ratios (PRs) for psychiatric comorbidities and psychotropic drug prescription at baseline were calculated using a fixed-effect Poisson regression model. All-person and sex-specific suicide and self-harm incidence rates per 10 000 personyears, with their 95% confidence intervals (CIs), were calculated for patients with and without psoriasis. Cox proportional hazard models stratified according to matched set were fitted to estimate hazard ratios (HRs) with 95% CIs for suicide and self-harm in people with psoriasis vs. the comparison cohort. The models were adjusted for area-level socioeconomic status measured by the IMD score. Additional analyses examining the risk of self-harm by psoriasis severity were performed. Here, the severity of psoriasis was modelled as a time-varying covariate based on systemic treatment exposure (acitretin, etretinate, ciclosporin, hydroxycarbamide, methotrexate, fumaric acid, phototherapy or a biological therapy). For both outcomes, interactions between psoriasis and age, sex and IMD quintile were tested separately.
To assess the robustness of the results, several sensitivity analyses were performed for both outcomes, as follows: (i) to explore the possibility of detection bias, the analysis was restricted to patients who consulted at least once a year during follow-up; (ii) the statistical model was rerun with the psoriasis cohort restricted to individuals without psoriatic arthritis; and (iii) the suicide definition was altered by excluding unnatural deaths of undetermined event. All statistical analyses were performed using Stata 14 (StataCorp, College Station, TX, U.S.A.).
Results
Demographics
The cohort for examining suicide included 56 961 patients with incident psoriasis diagnoses and 876 919 patients in the comparison group. Overall, there were more women (55Á3%) than men; the median age at the index date was 46 years (interquartile range 32-60) ( Table 1 ). Nested within this cohort, a slightly smaller study cohort for examining nonfatal selfharm as the outcome was also delineated, restricted to people without a history of self-harm prior to the index date, including 54 709 patients with psoriasis and 813 699 comparison patients. At baseline, 688 (1Á3%) patients with psoriasis had received phototherapy or systemic or biological therapies, which increased to 2491 (4Á6%) by the end of follow-up (Table S1 ; see Supporting Information).
Mental illness diagnoses and psychotropic medication prescribing
As shown in Table 2 , compared with the psoriasis-free cohort at baseline, patients with psoriasis had higher PRs (with 95% CIs) for histories of alcohol misuse (PR 1Á30, 1Á23-1Á37), bipolar disorder (PR 1Á23, 1Á10-1Á37), depression (PR 1Á17, 1Á15-1Á20), anxiety disorder (PR 1Á15, 1Á13-1Á18), self-harm (PR 1Á10, 1Á06-1Á15) and psychotropic medication prescription (PR 1Á13, 1Á12-1Á14). When removing people with a history of self-harm, the PRs for histories of alcohol misuse, mental illnesses and psychotropic medication prescription were lower but had a similar distribution.
Suicide and nonfatal self-harm risk
During a median (interquartile range) of 4Á4 (1Á8-8Á0) years of follow-up, 35 and 679 suicide deaths occurred in the psoriasis and comparison cohorts, respectively. Having excluded patients with a history of self-harm, 470 self-harm events occurred in the psoriasis cohort and 5281 such events occurred in the comparison group. Suicide rates were lower in the psoriasis cohort (1Á1 per 10 000 person-years) than in the comparison cohort (1Á5 per 10 000 person-years), whereas self-harm rates were higher in the psoriasis cohort (15Á0 per 10 000 person-years) than in the comparison cohort (12Á4 per 10 000 person-years) ( Table 3 ). The results from the Cox proportional hazards analysis showed that suicide risk in patients with psoriasis was significantly lower than in the comparison cohort having accounted for socioeconomic status (adjusted HR 0Á59, 95% CI 0Á41-0Á85). After excluding patients with a history of self-harm, there was a small and significant elevation in risk of self-harm among patients with psoriasis (HR 1Á15, 95% CI 1Á04-1Á27) ( Table 4) . Severe psoriasis was associated with a nonsignificantly elevated risk of self-harm: HR 1Á11 (95% CI 0Á63-1Á97) (Tables S2 and S3 ; see Supporting Information). An interaction test revealed a variation in suicide risk by age (P = 0Á017). The hazard ratio for suicide was 0Á92 (95% CI 0Á58-1Á46) for people with psoriasis diagnosed when they were younger than 40 years, whereas the HR was 0Á38 (95% CI 0Á21-0Á66) for people with psoriasis diagnosed at ≥ 40 years (Fig. 1) . There was no significant evidence of effect modification by sex (P = 0Á54) or by socioeconomic status (P = 0Á83). Similarly, no significant interactions were found in the cohort for examining self-harm between psoriasis and age (P = 0Á74), sex (P = 0Á92) or socioeconomic status (P = 0Á26).
Sensitivity analyses
For the suicide analysis, similar results were obtained when the analysis was restricted to patients who visited their general practitioner at least once a year or when we excluded unnatural deaths of 'undetermined intent' from the suicide definition. The HR for suicide slightly increased when patients with psoriatic arthritis were removed from the cohort, although it remained below unity and significantly so (Table 4) . Conversely, when the same set of sensitivity analyses was conducted for the examination of self-harm as the outcome, the results of the primary analysis were confirmed when people with psoriatic arthritis were excluded. However, when the cohort was restricted to patients who visited the practice at least once a year, the risk of self-harm remained slightly increased but no longer significantly so (HR 1Á10, 95% CI 0Á98-1Á22).
Discussion
Our large population-based cohort study has found lower suicide risk among people diagnosed with psoriasis than in individuals of the same age, sex and general practice without the condition. There was evidence of effect modification with age; specifically, the risk of suicide was lower among individuals diagnosed with psoriasis when they were ≥ 40 years old compared with people without the disease of the same age group, whereas if the diagnosis occurred prior to age 40 years there was no difference in risk compared with the matched comparison group. At the time of diagnosis, people with psoriasis had higher prevalences for histories of alcohol misuse, bipolar disorder, depression, anxiety disorders and self-harm, and were more likely to have been prescribed psychotropic medication. Following diagnosis, we found a small elevation in self-harm risk in the psoriasis group vs. the general population, and the risk of self-harm associated with severe psoriasis was also elevated but not significantly so. The robustness of our findings was assessed in a series of sensitivity analyses. When the analysis was restricted to people without psoriatic arthritis, the HR for suicide remained below unity. For the self-harm analysis, the results remained largely unchanged except for when the cohort was restricted to people visiting the general practitioner at least once a year, where the risk of self-harm associated with psoriasis was slightly elevated but no longer significantly so.
This study has several key strengths. Firstly, this was a very large population-based cohort study of more than 50 000 patients diagnosed with psoriasis that was well powered to investigate suicide as a rare, cause-specific mortality outcome. The large cohort size also enabled detailed exploration of effect modification by age, sex and area-level socioeconomic status. Importantly, the large number of comparison patients matched to each individual with psoriasis (1 : 20) allowed generation of precise estimates with narrow CIs. 20 Secondly, risks for fatal and nonfatal self-harm were analysed as two discrete outcomes in the same cohort at risk, which is advantageous in understanding the two phenomena separately. 26 Thirdly, linking primary care data with hospital records and mortality records enabled greater ascertainment of additional self-harm and suicide events than using the CPRD primary care records alone, 27 an approach that would have underestimated self-harm incidence by over 50%. 27 Fourthly, the 
IQR, interquartile range; CI, confidence interval. psoriasis cohort examined in this study was identified from a routinely collected primary care database. Therefore, our findings are likely to be more representative of all patients diagnosed with psoriasis in the population than in studies where the psoriasis cohort was identified solely from hospital episodes.
Some limitations of the study should also be considered in interpreting our findings. Firstly, given that general practitioners do not routinely record standardized information on disease severity, such as the Psoriasis Area and Severity Index score, the classification of severity of psoriasis according to prescribed medication presented challenges given that these treatments may have other indications. 28 Secondly, although we examined risk of self-harm according to psoriasis severity, it was not possible to investigate the risk of suicide by severity of psoriasis due to the fact that severe psoriasis has a much lower prevalence and suicide is a very rare outcome. Thirdly, although we exploited linkage between primary-and secondary-care data to enhance detection of self-harm events, it is likely that some events may not have been ascertained, as some patients do not present to general practice or hospitals following self-harm. 27 Finally, despite the steps taken to minimize surveillance bias, the raised prevalence of psychiatric comorbidities and psychotropic medication prescribing that we observed compared with persons without psoriasis might be due to affected individuals seeking care more often.
Comparison with other studies is challenging due to the different outcome definitions applied, such as whether or not self-harm and suicide were combined or analysed as discrete end points. Wu et al. 6 utilized an administrative database from the U.S.A. and reported a raised prevalence of depression [incidence rate ratio (IRR) 1Á14, 95% CI 1Á11-1Á17] in people with psoriasis. Using hospital records from England, Singhal et al. 12 investigated self-harm and suicide in patients with comorbid mental and physical illnesses. They found only a borderline significant association between psoriasis and suicide risk (rate ratio 1Á3, 95% CI 1Á0-1Á8) and evidence of greater self-harm risk associated with psoriasis than in the general population (rate ratio 1Á6, 95% CI 1Á5-1Á7).
More recently, a study from Denmark examined both nonfatal self-harm and suicide in patients with psoriasis from a large population-based study of more than 400 000 individuals. 13 The study showed no increased suicide risk in patients with mild (IRR 1Á05, 95% CI 0Á84-1Á32) or severe psoriasis (IRR 0Á78, 95% CI 0Á45-1Á36), whereas they found a significantly increased risk of self-harm associated with severe psoriasis (IRR 1Á69, 95% CI 1Á00-2Á84). Our findings are not directly comparable with those of Wu et al. 6 and Kurd et al., 4 who, using a primary care database from the U.K., reported an increased risk of suicidality, given that both studies investigated the risk of suicidality in people with psoriasis as a combined outcome (fatal and nonfatal suicide attempt). A summary of comparisons of these studies is provided in Table S4 (see Supporting Information). The main methodological differences between our cohort study and previously published investigations are as follows:
(i) varying outcome definitions (e.g. suicide and nonfatal selfharm analysed separately vs. combined as a single outcome variable); 4, 6 (ii) use of linked primary care, secondary care and mortality records, rather than primary care 4 or secondary care 12 alone, to enhance detection of outcomes of interest;
and (iii) identification of the psoriasis population from primary care rather than secondary care, 12 as being hospitalized for a major physical illness per se is linked with increased risk of suicide. 29 It is also noteworthy that the ratio of nonfatal self-harm to suicide events found in our study is in line with that reported by Singhal et al., 12 but does not concur with a
Danish study that indicated a higher number of suicide events than self-harm events. 13 Due to the classification system used, that study is likely to have captured only around a tenth of all the self-harm events that occurred in Denmark. 26, 30 Suicide and self-harm risks are complex behaviours influenced by many social, psychological and environmental factors. The findings herein indicate that healthcare professionals should be aware of the psychological burden that people with psoriasis carry by monitoring psychiatric comorbidities. This higher prevalence of psychiatric comorbidities may lead to a small elevation in self-harm risk associated with people affected by psoriasis. Interestingly, our findings showed a significantly reduced risk of suicide among people with psoriasis who were diagnosed at 40 years or older. Psoriasis has been classified as type I and II psoriasis according to whether the diagnosis occurs before (type I) or after 40 years of age (type II), 31 and these are often considered two distinct disorders with different clinical and genetic characteristics. 32 One possible explanation for the inverse relationship that we observed between type II psoriasis and suicide risk is competing risks for other causes of death. For instance, we have recently reported on an elevated risk of alcohol-related mortality. 33 Furthermore, our findings show that patients with psoriasis are treated more often for psychiatric comorbidities, and so their mood-related disorders, and consequently their suicide risk, may also be better monitored, treated and controlled than in persons without psoriasis.
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